Skip to main content
Fig. 3 | Malaria Journal

Fig. 3

From: Effectiveness and safety of artemether–lumefantrine versus artesunate–amodiaquine for unsupervised treatment of uncomplicated falciparum malaria in patients of all age groups in Nanoro, Burkina Faso: a randomized open label trial

Fig. 3

Kaplan–Meier survival curve of total risk of new infection. The figure shows the percentage of patients with new infection during the 28-day follow-up. The blue line indicates patients treated with artemether–lumefantrine (AL), the red line indicates patients treated with artesunate–amodiaquine (ASAQ)

Back to article page